MRKR

Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Marker Therapeutics, Inc. (MRKR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (C-). The rating has held at C+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
B
Factor Score 3.5 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.7
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -21.1%
Price Return 12M -3.2%
Catalyst Signal 0.00
Market Cap $15.0M
TTM Revenue $3.5M
Price / Sales 4.2
ROE -76.9%

Historical Factor Score Progression

Held C+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) B (3.5) C (2.4) C- (2.0) C+ (2.6) C+ (2.7)
2026-11-06 B- (3.0) B (3.5) C (2.4) C (2.3) C+ (2.7) C+ (2.8)
2026-10-30 B- (3.0) B (3.4) C (2.5) C (2.3) C+ (2.7) C+ (2.8)
2026-10-23 B- (3.0) B (3.4) C (2.4) C (2.4) C+ (2.6) C+ (2.8)
2026-10-16 B- (3.0) B (3.4) C (2.4) D+ (1.8) C+ (2.6) C+ (2.7)
Page 1 of 5